drugset / Trial / NCT04304040
A Study of MIL62 Combined With Orelabrutinib for the Treatment of R/R CD20+B Cell Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
Dose escalation and expansion phase I/IIa clinical study of recombinant humanized type II CD20 monoclonal antibody MIL62 injection combined with a novel selective Bruton Tyrosine Kinase(BTK) inhibitor Orelabrutinib in the treatment of recurrent/refractory CD20+B cell lymphoma
Timeline
- Start
- 2020-07-28
- Primary completion
- 2025-12-30
- Completion
- 2025-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MIL62 | Monoclonal antibody | 800 mg | — |
| Subject | MIL62 | Monoclonal antibody | 1000 mg | — |
| Subject | Orelabrutinib | Small molecule | — | — |